Vivos Therapeutics grants Krammer 12,000 options

Half of a director’s options vested immediately; the remaining options vest on September 30, 2026, and December 31, 2026.

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. director Anja B. Krammer received a grant of 12,000 stock options on September 14, 2026. The options are exercisable at $0.18 per share and expire on September 14, 2036. Half vested immediately; one-fourth will vest on September 30, 2026, and one-fourth on December 31, 2026. Her reported post-grant option position was 17,200 options.

Insider Trade Summary

Grant/Award: 12,000 shares

Grant/Award 1 txn

Insider Krammer Anja B

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy) F1	12,000	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 17,200 contracts (Direct)

Footnotes (1)

1. F1. On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date. Reflects expiry of 667 options on June 19, 2025 and 1,200 options on August 5, 2026, all of which expired unexercised.

Key Figures

Stock options granted: 12,000 options Exercise price: $0.18 per share Options following transaction: 17,200 options +3 more

6 metrics

Stock options granted 12,000 options Grant to director Anja B. Krammer on September 14, 2026

Exercise price $0.18 per share Options exercisable for common stock

Options following transaction 17,200 options Reported direct position after the September 14, 2026 grant

Immediate vesting One-half of the options Vested immediately on September 14, 2026

Scheduled vesting One-fourth of the options per installment September 30, 2026, and December 31, 2026

Option term 10 years From the September 14, 2026 grant date; expiration date September 14, 2036

Key Terms

stock options, vested immediately, exercisable, Grant Date

4 terms

stock options technical

"received a grant of 12,000 stock options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vested immediately technical

"One-half vested immediately"

exercisable technical

"options are exercisable for a period of 10 years"

Grant Date technical

"September 14, 2026 (the "Grant Date")"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VVOS stock options did Anja B. Krammer receive?

Anja B. Krammer received a grant of 12,000 stock options on September 14, 2026, with an exercise price of $0.18 per share. Her reported post-grant position was 17,200 options. The options expire on September 14, 2036.

When do Anja B. Krammer’s VVOS options vest?

Half of the options vested immediately on September 14, 2026. One-fourth will vest on September 30, 2026, and one-fourth on December 31, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 04:05 PM EDT Accepted by SEC EDGAR 10/27/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krammer Anja B

(Last) (First) (Middle)

7921 SOUTHPARK PLAZA,

SUITE 210

(Street)

LITTLETON COLORADO 80120

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vivos Therapeutics, Inc. [ VVOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)(1)	$0.18	09/14/2026		A		12,000		09/14/2026(1)	09/14/2036	Common Stock	12,000	$0	17,200(1)	D

Explanation of Responses:

1. On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date. Reflects expiry of 667 options on June 19, 2025 and 1,200 options on August 5, 2026, all of which expired unexercised.

	/s/ Bradford K. Amman as attorney-in-fact for Anja B. Krammer	10/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)